The acquisition will add to Isto Biologics’ portfolio of orthopedic grafts and bring TheraCell’s patented TheraFuze DBF technology to Isto’s Influx product line. Isto Biologics focuses on bone regeneration and cell-based therapies for orthopedics.
Isto Biologics is backed by private equity firm Thompson Street Capital Partners.
